About the Global Campaign
About the Global Campaign
In countries from the U.S. to Vietnam, Brazil to Indonesia, health groups are aiming to break Abbott’s monopoly control over lopinavir+ritonavir (Kaletra). Campaigners say Abbott’s high price for Kaletra is blocking expansion of AIDS treatment, and its anti-competitive practices are impeding new drug innovation.
Kaletra campaign flyer
Press Release (November 9, 2011)
Access Story Spotlight
“I wish the drug company would lower the price, as I know that the number of people taking Kaletra is growing higher and higher – and there are many more who can’t afford the treatment they need.” –Naza of Malaysia’s PT Foundation
Secondary Patenting: A Threat to Affordable Generic Patenting by I-MAK
Read about how Abbott is seeking to artificially extend its patents on lopinavir+ritonavir
Read full article here
Campaign Actions FAQ (Compulsory Licensing, Patent Opposition, March-In Request, Voluntary Licensing)
English | Español
TRIPS & Public Health FAQ – World Trade Organization
English | Español
Atazanavir Campaign News
- August 27, 2015 – Entrevista a Mario Rios de Justicia en Salud en el programa Exitosa Noticias
- August 27, 2015 – Entrevista a Mario Rios de Justicia en Salud en el programa San Borja Noticias
- August 22, 2015 – La Republica: PJ ordena al Minsa informar sobre licencia para Atazanavir
- July 14, 2015 – La Republica: Licencia obligatoria hubiera permitido 75% de ahorro en Atazanavir
- July 13, 2015 – La Republica: Bristol rebaja en 35% precio de fármaco contra el VIH, pero no deja el monopolio
- July 13, 2015 – Bolsamania: Antirretroviral Atazanavir cuesta 35% menos hoy que ayer pero aún es muy caro en Perú
- May 21, 2015 – Wall Street Journal: Bristol-Myers Faces a Compulsory License for an AIDS Drug in Peru
- April 28, 2015 – Public Citizen and IFARMA letter to INDECOPI on compulsory licensing
- April 28, 2015 – Civil society letter to Peruvian officials on atazanavir compuslory license (available in English here)
- April 28, 2015 – Academics letter to Peruvian officials on atazanavir compuslory license (available in English here)
- April 21, 2015 – Agenda Politica – Peruvian Minister of Health Anibal Velasquez on atazanavir compulsory license
- April 9, 2015 – LaRepublica.pe: Patentes dadas por Indecopi a fármacos afectan a la salud pública
- March 3, 2015 – LaRepublica.pe: Laboratorio presiona para conservar patente que costará a peruanos 130 millones de soles
- November 17, 2014 – Letter sent to President Ollanta Humala of Peru requesting a compulsory license on the HIV medication atazanavir in Peru
- November 17, 2014 – Letter sent to Ministry of Health of Peru requesting a compulsory license on the HIV medication atazanavir in Peru
- August 14, 2014 – LaRepublica.pe – Sobregasto en medicamentos (en español)
- June 19, 2014 – Patente en ARV: Caso atazanavir (courtesy of Javier Llamoza; en español)
- April 17, 2014 – Peruvian Civil Society Organizations Demand that Government Issue a Compulsory License for Atazanavir (links to infojustice.org)
Atazanavir in the News
- July 14, 2015 – La Republica: Licencia obligatoria hubiera permitido 75% de ahorro en Atazanavir
- July 13, 2015 – La Republica: Bristol rebaja en 35% precio de fármaco contra el VIH, pero no deja el monopolio
- July 13, 2015 – Bolsamania: Antirretroviral Atazanavir cuesta 35% menos hoy que ayer pero aún es muy caro en Perú
- May 21, 2015 – Wall Street Journal: Bristol-Myers Faces a Compulsory License for an AIDS Drug in Peru
- April 21, 2015 – Agenda Politica – Peruvian Minister of Health Anibal Velasquez on atazanavir compulsory license
- April 9, 2015 – LaRepublica.pe: Patentes dadas por Indecopi a fármacos afectan a la salud pública
- March 3, 2015 – LaRepublica.pe: Laboratorio presiona para conservar patente que costará a peruanos 130 millones de soles
- January 20, 2015 – teleSUR: Peru: Patients Demand End to Monopoly on HIV Medication
- January 20, 2015 – NTN24: Ante riesgo de suspensión de dosis, peruanos con VIH exigen que se declare de interés público medicamento
- January 21, 2015 – Diario Uno: Alto al monopolio de retrovirales
- January 21, 2015 – LaRepublica.pe: Pacientes con VIH piden antirretroviral genérico
- January 21, 2015 – teleSUR English: Multi-nationals have monopoly on HIV medicines in Peru
Kaletra Campaign News
- October 31, 2013 – The Economic Times: Patent office rejects BDR Pharma’s compulsory licensing application
- August 6, 2013 – Kractivism: Press Release- Campaign for Affordable Trastuzumab (links to kractivist.org)
- August 5, 2013 – Bio World: China Revokes Viread Patent; Pricing Was at Issue (links to bioworld.com)
- May 30, 2013 – The Jakarta Globe: Future Hepatitis C Blockbusters May Spawn Compulsory Generics (links to thejakartaglobe.com)
- March 18, 2013 – ACTION! Essential Inventions issues request for non-voluntary authorization to use patents under Article 14 of Greece patent law (links to essentialinventions.org)
- March 17, 2013 – Financial Times: Athens urged to import generic drugs (links to ft.com)
- December, 2012 – Secondary Patenting: A Threat to Affordable Generic Patenting by I-MAK
- November 2, 2012 – Nature: NIH asked to grant open license on HIV drug (links to blogs.nature.com)
- October 25, 2012 – ACTION! Knowledge Ecology International: Four NGOs ask NIH to grant open licenses to ritonavir patents under Bayh-Dole March-in provisions (links to keionline.org)
- October 22, 2012 – The Star (Malaysia): Measure to make drugs affordable (links to thestar.com.my)
- October 12, 2012 – Reuters: Indonesia acts to over-ride patents on HIV drugs (links to uk.reuters.com)
- October 11, 2012 – ACTION! The Guardian: Indonesia in bold move to obtain cheap drugs for HIV (links to guardian.co.uk)
Return to the Kaletra Campaign Homepage